Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Such a collaboration successfully provided treatment to a population of Native Americans and Alaska Natives.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Researchers analyzed 10 biomarkers associated with biological aging among a group of HIV-positive and -negative Europeans.
The U.S. Preventive Services Task Force has reaffirmed its 2009 recommendation.
Cabometyx is the third liver cancer drug approved in the past six months.
Those who exercise build up less liver fat, which is tied to inflammation that may give rise to cancer.
Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.
Researchers compared direct-acting-antiviral treatment outcomes between those with and without a history of liver cancer.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
This holds true regardless of how long they’ve had HIV or whether they’re on antiretrovirals.
Non-alcoholic steatohepatitis, or NASH, is a form of non-alcoholic fatty liver disease.
Researchers say given the many associated downsides and risks, opioids should not be a first choice for chronic noncancer pain.
Differences in the severity of the opioid epidemic are likely partial drivers of such variations.
The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
In a cohort of British individuals who contracted hep C as children, one third developed cirrhosis, at a median age of 32 years old.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.